Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
Background: Antifibrotic agents have been approved for the treatment of idiopathic pulmonary fibrosis (IPF). However, the efficacy of these drugs in the treatment of familial IPF (FIPF) has not been previously reported. Case presentation: We report the case of a 77-year-old man with FIPF, successfully treated with pirfenidone. His uncle died due to IPF, and his niece was diagnosed with the disease. He had worsening dyspnea two months prior to admission to our hospital. Upon admission, he had desaturation when exercising and broad interstitial pneumonia. Administration of pirfenidone improved his dyspnea, desaturation, and the reticular shadow on his chest radiograph. Increased fibrotic marker levels KL-6 and SP-D were also normalized in six months; treatment had no effect on his serum periostin level. Pirfenidone has been effective for over two years. Conclusion: Antifibrotic agents such as pirfenidone may be useful for the management of FIPF, as well as cases of sporadic IPF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Medicina (Kaunas, Lithuania) - 55(2019), 5 vom: 17. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koga, Yasuhiko [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.12.2019 Date Revised 25.02.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/medicina55050161 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM297274430 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM297274430 | ||
| 003 | DE-627 | ||
| 005 | 20231225091633.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/medicina55050161 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0990.xml |
| 035 | |a (DE-627)NLM297274430 | ||
| 035 | |a (NLM)31108995 | ||
| 035 | |a (PII)E161 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koga, Yasuhiko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.12.2019 | ||
| 500 | |a Date Revised 25.02.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Antifibrotic agents have been approved for the treatment of idiopathic pulmonary fibrosis (IPF). However, the efficacy of these drugs in the treatment of familial IPF (FIPF) has not been previously reported. Case presentation: We report the case of a 77-year-old man with FIPF, successfully treated with pirfenidone. His uncle died due to IPF, and his niece was diagnosed with the disease. He had worsening dyspnea two months prior to admission to our hospital. Upon admission, he had desaturation when exercising and broad interstitial pneumonia. Administration of pirfenidone improved his dyspnea, desaturation, and the reticular shadow on his chest radiograph. Increased fibrotic marker levels KL-6 and SP-D were also normalized in six months; treatment had no effect on his serum periostin level. Pirfenidone has been effective for over two years. Conclusion: Antifibrotic agents such as pirfenidone may be useful for the management of FIPF, as well as cases of sporadic IPF | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a familial | |
| 650 | 4 | |a idiopathic interstitial pneumonia | |
| 650 | 4 | |a idiopathic pulmonary fibrosis | |
| 650 | 4 | |a periostin | |
| 650 | 4 | |a pirfenidone | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 650 | 7 | |a MUC1 protein, human |2 NLM | |
| 650 | 7 | |a Mucin-1 |2 NLM | |
| 650 | 7 | |a POSTN protein, human |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactant-Associated Protein A |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactant-Associated Protein D |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 650 | 7 | |a pirfenidone |2 NLM | |
| 650 | 7 | |a D7NLD2JX7U |2 NLM | |
| 700 | 1 | |a Hachisu, Yoshimasa |e verfasserin |4 aut | |
| 700 | 1 | |a Tsurumaki, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yatomi, Masakiyo |e verfasserin |4 aut | |
| 700 | 1 | |a Kaira, Kyoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Ohta, Shoichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Ono, Junya |e verfasserin |4 aut | |
| 700 | 1 | |a Izuhara, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Dobashi, Kunio |e verfasserin |4 aut | |
| 700 | 1 | |a Hisada, Takeshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina (Kaunas, Lithuania) |d 1998 |g 55(2019), 5 vom: 17. Mai |w (DE-627)NLM093687583 |x 1648-9144 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2019 |g number:5 |g day:17 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/medicina55050161 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2019 |e 5 |b 17 |c 05 | ||